Treatment with recombinant human activated protein C obviates additional anticoagulation during continuous venovenous hemofiltration in patients with severe sepsis

被引：13

作者：

de Pont, ACJM ^{[1
]}

Bouman, CSC ^{[1
]}

de Jonge, E ^{[1
]}

Vroom, MB ^{[1
]}

Büller, HR ^{[1
]}

Levi, M ^{[1
]}

机构：

[1] Univ Amsterdam, Acad Med Ctr, Adult Intens Care Unit, NL-1105 AZ Amsterdam, Netherlands

来源：

INTENSIVE CARE MEDICINE | 2003年 / 29卷 / 07期

关键词：

D O I：

10.1007/s00134-003-1781-4

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

引用

页码：1205 / 1205

页数：1

共 5 条

[1] Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].

Bernard, GR ;

Vincent, JL ;

Laterre, P ;

LaRosa, SP ;

Dhainaut, JF ;

Lopez-Rodriguez, A ;

Steingrub, JS ;

Garber, GE ;

Helterbrand, JD ;

Ely, EW ;

Fisher, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709

[2] Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration [J].

Cardigan, RA ;

McGloin, H ;

Mackie, IJ ;

Machin, SJ ;

Singer, M .

KIDNEY INTERNATIONAL, 1999, 55 (04) :1568-1574

[3] Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation [J].

Esmon, CT .

CRITICAL CARE MEDICINE, 2001, 29 (07) :S48-S51

[4] Regulation of blood coagulation [J].

Esmon, CT .

BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 2000, 1477 (1-2) :349-360

[5]

Gori AM, 1999, THROMB HAEMOSTASIS, V81, P589

← 1 →